Pharmacosurveillance study of FDA Adverse Event Reporting System (FAERS) events of Tirzepatide and Semaglutide

被引：0
|
作者：
Logvinsky, Ilana
Barlas, Sait
Maddineni, Gautam
Wood, Malissa
Delibasic, Maja
机构：
来源：
CIRCULATION | 2024年 / 150卷
关键词：
D O I：
10.1161/circ.150.suppl_1.4142273
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4142273
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS) Events of Tofacitinib and Upadacitinib
    Barlas, Nur
    Barlas, Sait
    Milutinovic, Stefan
    Basnyat, Shristi
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2058 - 2059
  • [2] Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023
    Godfrey, Hannah
    Leibovit-Reiben, Zachary
    Jedlowski, Patrick
    Thiede, Rebecca
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2025, 39 (02) : e153 - e154
  • [3] Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
    Wen, Ming-Tao
    Li, Jia-Cheng
    Lu, Bo-Wen
    Shao, Hua-Rong
    Ling, Pei-Xue
    Liu, Fei
    Li, Gang
    Luo, Di
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [4] Pharmacovigilance Analysis Of FDA Adverse Event Reporting System (FAERS) Events For Inclisiran
    Rajak, Kripa
    Halder, Anupam
    Gautam, Seema Sharma
    Khanal, Resha
    Atrash, Anas
    Goswami, Rohan
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2023, 43
  • [5] A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor
    Pan, Yunyan
    Wang, Yu
    Zheng, Yifan
    Chen, Jie
    Li, Jia
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [6] Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
    Shu, Yamin
    He, Xucheng
    Wu, Pan
    Liu, Yanxin
    Ding, Yufeng
    Zhang, Qilin
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [7] A REALWORLD PHARMACOVIGILANCE STUDY OF FDA ADVERSE EVENT REPORTING SYSTEM (FAERS) EVENTS FOR EMPAGLIFLOZIN AND DAPAGLIFLOZIN
    Milutinovic, Stefan
    Petrovic, Marija
    Jancic, Predrag
    Trajkovic, Hristina
    Alarcon, Ricardo Orlando Escarcega
    Chazal, Richard A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 319 - 319
  • [8] A real-world disproportionality analysis of tirzepatide-related adverse events based on the FDA Adverse Event Reporting System (FAERS) database
    Li, Jie
    Xie, Jun
    Han, Yi
    Zhang, Wei
    Wang, Yilei
    Jiang, Zhitao
    ENDOCRINE JOURNAL, 2025, 72 (03) : 273 - 283
  • [9] A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database
    Liu, Liyuan
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [10] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Shu-peng Zou
    Hai-yun Yang
    Meng-ling Ouyang
    Qian Cheng
    Xuan Shi
    Ming-hui Sun
    BMC Pharmacology and Toxicology, 24
12345